Viatris (VTRS) Stock Forecast, Price Target & Predictions
VTRS Stock Forecast
Viatris stock forecast is as follows: an average price target of $15.00 (represents a 20.77% upside from VTRS’s last price of $12.42) and a rating consensus of 'Hold', based on 7 wall street analysts offering a 1-year stock forecast.
VTRS Price Target
The average price target for Viatris (VTRS) is $15.00 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $15.00 to $15.00. This represents a potential 20.77% upside from VTRS's last price of $12.42.
VTRS Analyst Ratings
According to 7 Wall Street analysts, Viatris's rating consensus is 'Hold'. The analyst rating breakdown for VTRS stock is 0 'Strong Buy' (0.00%), 1 'Buy' (14.29%), 5 'Hold' (71.43%), 1 'Sell' (14.29%), and 0 'Strong Sell' (0.00%).
Viatris Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Jul 19, 2024 | Glen Santangelo | Jefferies | $15.00 | $11.77 | 27.44% | 20.77% |
Mar 28, 2024 | David Amsellem | Piper Sandler | $13.00 | $11.83 | 9.89% | 4.67% |
Jun 26, 2023 | David Amsellem | Piper Sandler | $10.00 | $9.84 | 1.68% | -19.48% |
Feb 01, 2023 | Barclays | $15.00 | $12.16 | 23.36% | 20.77% | |
Nov 09, 2022 | Ashwani Verma | UBS | $12.00 | $10.83 | 10.80% | -3.38% |
Jun 13, 2022 | Ashwani Verma | UBS | $9.00 | $10.77 | -16.43% | -27.54% |
The latest Viatris stock forecast, released on Jul 19, 2024 by Glen Santangelo from Jefferies, set a price target of $15.00, which represents a 27.44% increase from the stock price at the time of the forecast ($11.77), and a 20.77% increase from VTRS last price ($12.42).
Viatris Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 2 |
Avg Price Target | - | - | $14.00 |
Last Closing Price | $12.42 | $12.42 | $12.42 |
Upside/Downside | -100.00% | -100.00% | 12.72% |
In the current month, the average price target of Viatris stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Viatris's last price of $12.42. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Mar 28, 2024 | Piper Sandler | Neutral | Neutral | Hold |
Jan 12, 2024 | Cowen & Co. | Market Perform | Downgrade | |
Dec 27, 2023 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
Sep 27, 2023 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
Jun 26, 2023 | BMO Capital | Perform | Market Perform | Downgrade |
Feb 17, 2023 | BMO Capital | Market Perform | Perform | Downgrade |
Feb 17, 2023 | BMO Capital | Market Perform | Downgrade | |
Feb 01, 2023 | Barclays | Overweight | Overweight | Hold |
Nov 08, 2022 | Piper Sandler | Neutral | Upgrade | |
Jun 13, 2022 | UBS | Sell | Initialise |
Viatris's last stock rating was published by Piper Sandler on Mar 28, 2024. The company gave VTRS a "Neutral" rating, the same as its previous rate.
Viatris Financial Forecast
Viatris Revenue Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | $3.94B | $3.92B | $3.73B | $3.88B | $4.08B | $4.12B | $4.19B | $4.34B | $4.54B | $4.58B | $4.43B | $3.62B | $2.97B | $2.73B | $2.62B | $3.19B | $2.96B | $2.85B | $2.50B | $2.68B | $2.72B |
Avg Forecast | $3.62B | $3.71B | $3.61B | $3.51B | $3.62B | $3.72B | $3.78B | $3.69B | $3.89B | $4.00B | $3.86B | $3.80B | $3.99B | $4.14B | $4.18B | $4.23B | $4.35B | $4.39B | $4.40B | $4.20B | $4.17B | $3.00B | $2.74B | $2.65B | $3.22B | $3.01B | $2.81B | $2.69B | $2.68B | $2.69B |
High Forecast | $3.62B | $3.72B | $3.62B | $3.52B | $3.63B | $3.74B | $3.79B | $3.69B | $3.95B | $4.00B | $3.87B | $3.81B | $4.00B | $4.14B | $4.18B | $4.23B | $4.35B | $4.39B | $4.40B | $4.20B | $4.17B | $3.00B | $2.74B | $2.65B | $3.22B | $3.01B | $2.81B | $2.69B | $3.22B | $3.23B |
Low Forecast | $3.61B | $3.70B | $3.60B | $3.51B | $3.61B | $3.69B | $3.77B | $3.69B | $3.84B | $4.00B | $3.85B | $3.79B | $3.98B | $4.14B | $4.18B | $4.23B | $4.35B | $4.39B | $4.40B | $4.20B | $4.17B | $3.00B | $2.74B | $2.65B | $3.22B | $3.01B | $2.81B | $2.69B | $2.15B | $2.15B |
# Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 10 | 16 | 8 | 11 | 7 | 11 | 7 | 7 | 17 | 19 |
Surprise % | - | - | - | - | - | - | - | - | - | 0.99% | 1.01% | 0.98% | 0.97% | 0.99% | 0.98% | 0.99% | 1.00% | 1.03% | 1.04% | 1.06% | 0.87% | 0.99% | 1.00% | 0.99% | 0.99% | 0.98% | 1.01% | 0.93% | 1.00% | 1.01% |
Viatris's average Quarter revenue forecast for Dec 23 based on 4 analysts is $3.89B, with a low forecast of $3.84B, and a high forecast of $3.95B. VTRS's average Quarter revenue forecast represents a -1.40% decrease compared to the company's last Quarter revenue of $3.94B (Sep 23).
Viatris EBITDA Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 10 | 16 | 8 | 11 | 7 | 11 | 7 | 7 | 17 | 19 |
EBITDA | - | - | - | - | - | - | - | - | - | $451.70M | $369.20M | $470.30M | $1.64B | $576.80M | $546.10M | $679.90M | $963.20M | $1.37B | $1.30B | $1.17B | $148.90M | $801.30M | $571.50M | $581.00M | $812.80M | $732.10M | $601.80M | $513.50M | $641.30M | $624.00M |
Avg Forecast | $954.43M | $979.49M | $952.52M | $927.31M | $955.28M | $980.88M | $998.16M | $1.45B | $1.03B | $1.06B | $1.02B | $1.32B | $790.19M | $1.10B | $1.11B | $1.20B | $1.15B | $1.16B | $1.17B | $977.67M | $1.11B | $794.78M | $724.43M | $539.29M | $852.54M | $796.45M | $744.52M | $497.56M | $640.70M | $618.50M |
High Forecast | $956.80M | $981.92M | $954.88M | $929.61M | $957.91M | $988.02M | $1.00B | $1.74B | $1.04B | $1.06B | $1.02B | $1.59B | $948.23M | $1.10B | $1.11B | $1.44B | $1.15B | $1.16B | $1.17B | $1.17B | $1.11B | $794.78M | $724.43M | $647.15M | $852.54M | $796.45M | $744.52M | $597.07M | $768.84M | $742.20M |
Low Forecast | $952.76M | $977.77M | $950.84M | $925.68M | $952.65M | $973.73M | $996.41M | $1.16B | $1.01B | $1.06B | $1.02B | $1.06B | $632.16M | $1.10B | $1.11B | $960.68M | $1.15B | $1.16B | $1.17B | $782.14M | $1.11B | $794.78M | $724.43M | $431.43M | $852.54M | $796.45M | $744.52M | $398.05M | $512.56M | $494.80M |
Surprise % | - | - | - | - | - | - | - | - | - | 0.43% | 0.36% | 0.36% | 2.08% | 0.53% | 0.49% | 0.57% | 0.84% | 1.18% | 1.11% | 1.20% | 0.13% | 1.01% | 0.79% | 1.08% | 0.95% | 0.92% | 0.81% | 1.03% | 1.00% | 1.01% |
4 analysts predict VTRS's average Quarter EBITDA for Dec 23 to be $1.03B, with a high of $1.04B and a low of $1.01B. This is 127.15% upper than Viatris's previous annual EBITDA (Sep 23) of $451.70M.
Viatris Net Income Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 10 | 16 | 8 | 11 | 7 | 11 | 7 | 7 | 17 | 19 |
Net Income | - | - | - | - | - | - | - | - | - | $331.60M | $264.00M | $224.70M | $1.01B | $354.30M | $313.90M | $399.20M | $-263.80M | $311.50M | $-279.20M | $-1.04B | $-915.80M | $185.70M | $39.40M | $20.80M | $20.50M | $189.80M | $-168.50M | $-25.00M | $87.10M | $66.40M |
Avg Forecast | $790.62M | $815.52M | $759.25M | $754.54M | $694.02M | $812.42M | $814.44M | $411.47M | $775.85M | $895.93M | $853.22M | $374.07M | $-300.67M | $997.45M | $988.76M | $340.06M | $986.80M | $1.05B | $1.04B | $-881.96M | $1.48B | $1.39B | $1.18B | $19.83M | $1.53B | $1.35B | $1.12B | $-24.05M | $87.10M | $65.68M |
High Forecast | $793.16M | $818.14M | $761.70M | $756.97M | $717.96M | $819.74M | $814.71M | $493.77M | $810.59M | $899.75M | $855.97M | $448.88M | $-240.53M | $997.45M | $988.76M | $408.07M | $986.80M | $1.05B | $1.04B | $-705.57M | $1.48B | $1.39B | $1.18B | $23.80M | $1.53B | $1.35B | $1.12B | $-19.24M | $104.52M | $78.81M |
Low Forecast | $788.82M | $813.66M | $757.52M | $752.81M | $658.13M | $805.10M | $814.16M | $329.18M | $706.38M | $892.11M | $851.28M | $299.25M | $-360.80M | $997.45M | $988.76M | $272.05M | $986.80M | $1.05B | $1.04B | $-1.06B | $1.48B | $1.39B | $1.18B | $15.87M | $1.53B | $1.35B | $1.12B | $-28.86M | $69.68M | $52.54M |
Surprise % | - | - | - | - | - | - | - | - | - | 0.37% | 0.31% | 0.60% | -3.36% | 0.36% | 0.32% | 1.17% | -0.27% | 0.30% | -0.27% | 1.18% | -0.62% | 0.13% | 0.03% | 1.05% | 0.01% | 0.14% | -0.15% | 1.04% | 1.00% | 1.01% |
Viatris's average Quarter net income forecast for Dec 23 is $775.85M, with a range of $706.38M to $810.59M. VTRS's average Quarter net income forecast represents a 133.97% increase compared to the company's last Quarter net income of $331.60M (Sep 23).
Viatris SG&A Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 10 | 16 | 8 | 11 | 7 | 11 | 7 | 7 | 17 | 19 |
SG&A | - | - | - | - | - | - | - | - | - | $1.05B | $1.03B | $958.90M | $1.27B | $1.02B | $981.10M | $915.30M | $1.08B | $1.05B | $1.20B | $1.19B | $1.36B | $658.40M | $719.40M | $605.40M | $654.40M | $632.70M | $668.60M | $607.90M | $607.50M | $631.30M |
Avg Forecast | $946.68M | $971.53M | $944.78M | $919.78M | $947.52M | $972.91M | $990.05M | $943.44M | $1.02B | $1.05B | $1.01B | $857.67M | $1.23B | $1.08B | $1.10B | $779.70M | $1.14B | $1.15B | $1.15B | $1.01B | $1.09B | $785.80M | $716.25M | $577.24M | $842.91M | $787.45M | $736.11M | $584.82M | $607.50M | $624.44M |
High Forecast | $949.02M | $973.94M | $947.12M | $922.06M | $950.13M | $979.99M | $992.51M | $1.13B | $1.03B | $1.05B | $1.01B | $1.03B | $1.48B | $1.08B | $1.10B | $935.64M | $1.14B | $1.15B | $1.15B | $1.21B | $1.09B | $785.80M | $716.25M | $692.69M | $842.91M | $787.45M | $736.11M | $701.78M | $729.00M | $749.33M |
Low Forecast | $945.01M | $969.82M | $943.12M | $918.16M | $944.91M | $965.82M | $988.31M | $754.75M | $1.00B | $1.05B | $1.01B | $686.14M | $987.40M | $1.08B | $1.10B | $623.76M | $1.14B | $1.15B | $1.15B | $806.82M | $1.09B | $785.80M | $716.25M | $461.79M | $842.91M | $787.45M | $736.11M | $467.85M | $486.00M | $499.55M |
Surprise % | - | - | - | - | - | - | - | - | - | 1.01% | 1.02% | 1.12% | 1.03% | 0.94% | 0.90% | 1.17% | 0.95% | 0.92% | 1.05% | 1.18% | 1.25% | 0.84% | 1.00% | 1.05% | 0.78% | 0.80% | 0.91% | 1.04% | 1.00% | 1.01% |
Viatris's average Quarter SG&A projection for Dec 23 is $1.02B, based on 4 Wall Street analysts, with a range of $1.00B to $1.03B. The forecast indicates a -3.40% fall compared to VTRS last annual SG&A of $1.05B (Sep 23).
Viatris EPS Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 10 | 16 | 8 | 11 | 7 | 11 | 7 | 7 | 17 | 19 |
EPS | - | - | - | - | - | - | - | - | - | $0.28 | $0.22 | $0.19 | $0.83 | $0.29 | $0.26 | $0.33 | $-0.22 | $0.26 | $-0.23 | $-0.86 | $-0.76 | $0.36 | $0.08 | $0.04 | $0.04 | $0.37 | $-0.33 | $-0.05 | $0.17 | $0.12 |
Avg Forecast | $0.66 | $0.68 | $0.63 | $0.63 | $0.58 | $0.68 | $0.68 | $0.67 | $0.65 | $0.75 | $0.71 | $0.69 | $0.72 | $0.84 | $0.83 | $0.83 | $0.83 | $0.88 | $0.87 | $0.80 | $1.24 | $1.16 | $0.99 | $0.86 | $1.29 | $1.13 | $0.94 | $0.79 | $0.96 | $0.91 |
High Forecast | $0.66 | $0.68 | $0.63 | $0.63 | $0.60 | $0.68 | $0.68 | $0.67 | $0.68 | $0.75 | $0.71 | $0.69 | $0.72 | $0.84 | $0.83 | $0.83 | $0.83 | $0.88 | $0.87 | $0.80 | $1.24 | $1.16 | $0.99 | $0.86 | $1.29 | $1.13 | $0.94 | $0.79 | $1.15 | $1.09 |
Low Forecast | $0.66 | $0.68 | $0.63 | $0.63 | $0.55 | $0.67 | $0.68 | $0.67 | $0.59 | $0.74 | $0.71 | $0.68 | $0.72 | $0.84 | $0.83 | $0.83 | $0.83 | $0.88 | $0.87 | $0.80 | $1.24 | $1.16 | $0.99 | $0.86 | $1.29 | $1.13 | $0.94 | $0.79 | $0.77 | $0.73 |
Surprise % | - | - | - | - | - | - | - | - | - | 0.38% | 0.31% | 0.28% | 1.16% | 0.35% | 0.31% | 0.40% | -0.27% | 0.29% | -0.26% | -1.08% | -0.61% | 0.31% | 0.08% | 0.05% | 0.03% | 0.33% | -0.35% | -0.06% | 0.18% | 0.13% |
According to 4 Wall Street analysts, Viatris's projected average Quarter EPS for Dec 23 is $0.65, with a low estimate of $0.59 and a high estimate of $0.68. This represents a 130.83% increase compared to VTRS previous annual EPS of $0.28 (Sep 23).
Viatris Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
EBS | Emergent BioSolutions | $8.79 | $51.50 | 485.89% | Buy |
TLRY | Tilray Brands | $1.24 | $2.25 | 81.45% | Hold |
LNTH | Lantheus | $92.66 | $155.00 | 67.28% | Buy |
ELAN | Elanco Animal Health | $12.31 | $17.50 | 42.16% | Buy |
ZTS | Zoetis | $170.79 | $221.00 | 29.40% | Buy |
VTRS | Viatris | $12.59 | $15.00 | 19.14% | Hold |
HCM | HUTCHMED (China) | $14.86 | $17.50 | 17.77% | Buy |
TEVA | Teva Pharmaceutical Industries | $20.88 | $23.20 | 11.11% | Buy |
BHC | Bausch Health Companies | $7.68 | $8.33 | 8.46% | Hold |
CTLT | Catalent | $63.48 | $63.50 | 0.03% | Hold |
HLN | Haleon | $9.91 | $9.15 | -7.67% | Buy |